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Abstract
Multidrug resistance (MDR) caused by overexpression of p-glycoprotein is a major obstacle in chemotherapy of malignant
cancer, which usually is characterized by constitutive activation of signal transducer and activator of transcription 3 (STAT3),
but their relation between MDR and STAT3 remains unclear. Here, we showed that STAT3 was overexpressed and highly
activated in adriamycin-resistant K562/A02 cells compared with its parental K562 cells. Blockade of activation of STAT3 by
STAT3 decoy oligodeoxynucleotide (ODN) promoted the accumulation and increased their sensitivity to adriamycin by
down-regulating transcription of mdr1 and expression of P-gp, which were further confirmed by using STAT3-specific
inhibitor JSI-124. Inhibition of STAT3 could also decrease mdr1 promoter mediated luciferase expression by using mdr1
promoter luciferase reporter construct. Otherwise, activation of STAT3 by STAT3C improved mdr1 transcription and P-gp
expression. The ChIP results demonstrated that STAT3 could bind to the potential promoter region of mdr1, and STAT3
decoy depressed the binding. Further mutation assay show +64,+72 region could be the STAT3 binding site. Our data
demonstrate a role of STAT3 in regulation of mdr1 gene expression in myeloid leukemia and suggest that STAT3 may be a
promising therapeutic target for overcoming MDR resistance in myeloid leukemia.
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Introduction
Leukemia is the sixth most lethal cancer accounting for 4% of
all cancers, and the most common childhood cancer accounting
for 32.6% of all childhood cancers. Chemotherapy is the most
effective method for leukemia treatment. However, a 5-year
relative survival ratio is only about 50% due to MDR (American
Cancer Society). Several potential molecular or cellular mecha-
nisms responsible for MDR have been elucidated. The over-
expression of P-gp, encoded by the ATP Binding Cassette B1
(ABCB1, also known as mdr1) gene, is considered as one of the
major obstacles to successful cancer chemotherapy.[1] P-gp is a
trans-membrane glycoprotein which reduces intracellular drug
concentrations by pumping drugs out of the cells.[2] Numerous
studies have confirmed that the expression of P-gp is an adverse
prognostic factor for complete remission and survival in adult
AML.[3,4] Unfortunately, the efflux-pump modulators used in
clinic have been proved disappointing. This is at least to a certain
extent because the fundamental molecular mechanisms driving
MDR phenotype of leukemia cells remain obscure. Therefore, the
characterization of signaling pathways about MDR leukemia is
very important for designing rational novel therapies.
STAT3 is constitutively activated in diverse human cancers
including primary leukemia and leukemia derived cell lines.[5,6]
The activity of STAT3 has been implicated in tumor cell survival,
inhibition of apoptosis, proliferation, motility, angiogenesis,
invasion and metastasis.[6] The constantly activated STAT3
contributes to oncogenesis by up-regulation of genes encoding bcl-
xl, cyclin D1, mcl-1, and VEGF, IL-10, TGF-b et al.[6] Our
previous study also showed that blockage of STAT3 by decoy
ODN decreased proliferation and induced apoptosis by down-
regulating its target genes in vitro and in vivo.[7,8]
Constitutive activation of STAT3 has been shown to confer
resistance to chemotherapy-induced apoptosis in some malignan-
cies. For example, inhibition of Src not only sensitized ovarian
cancer cells to chemotherapeutic agents but also re-sensitized
paclitaxel-resistant cells to paclitaxel.[9] Blockade of STAT3 with
the STAT3 decoy ODN augmented apoptosis when combined
with cisplatin both in vitro and in vivo.[10] Inhibition of STAT3
activity enhanced chemosensitivity in hepatocellular, stomach
carcinoma and melanoma.[11,12,13] Additionally, some research-
ers demonstrated that multidrug resistance was consistent with
STAT3 mRNA over-expression in cisplatin-resistant lung cancer
cells [14] and STAT3 activity specifically elevated in drug-resistant
neuroblastoma and ovarian cells, while not in relevant drug-
sensitive cells.[15] Recently, it was demonstrated that inhibition of
STAT3 effectively enhanced multidrug sensitivity via inhibiting
Nanog/STAT3-mediated mdr1 gene expression in both MCF-7
cells and SK-OV-3.ipl cells.[16] In clinic, STAT3 is highly
activated in drug non-sensitive advanced tumors. All these findings
PLoS ONE | www.plosone.org 1 June 2011 | Volume 6 | Issue 6 | e20965suggested that STAT3 might be associated with MDR and their
relation needed to be defined, and this study therefore aimed at
deciphering the potential role of STAT3 in chemotherapy
resistance in leukemia.
In this study, the results presented that elevated expression and
constitutive activation of STAT3 was observed in adriamycin-
resistant K562/A02 cells. Inhibition of STAT3 increased the
sensitivity of K562/A02 cells to adriamycin by down-regulating
mdr1. All these findings suggested that STAT3 signaling may be an
interesting target for reverting (or preventing) chemoresistance in
myeloid leukemia.
Materials and Methods
Cell culture
The human leukemia sensitive parental K562 cell was obtained
from the American Type Culture Collection (Rockville, MD) and
adriamycin-selected MDR K562/A02 subline was obtained from
the Institute of Hematology of Chinese Academy of Medical
Sciences (Tianjin, China).[17] K562/A02 displayed 310-flod
resistance to adriamycin.[18] MCF-7 and MCF-7/ADR was
obtained from Cancer Institute & Hospital of Chinese Academy of
Medical Sciences. Cells were cultured in DEME medium
(GIBCO/BRL) containing 10% (V/V) fetal calf serum (FCS,
GIBCO/BRL), 100IU/ml penicillin and 100 mg/ml streptomycin
in 5% CO2 at 37uC. K562/A02 and MCF-7/ADR cells were
routinely maintained in medium containing 200 mg/L or 1mg/L
adriamycin, respectively.[17] We concluded that the comparison
of K562 and K562/A02 constitutes a valid model to study induced
resistance for classical chemotherapy.
Antibodies and reagents
Anti-STAT3, anti-phospho-specific STAT3 (Tyr705, Ser727),
anti-b-actin antibodies and horseradish peroxidase-conjugated
second antibody were purchased from Cell Signaling Technology.
Anti-P-gp was purchased from Santa Cruz (Santa Cruz Biotech-
nology, Inc.). STAT3 inhibitor JSI-124 was purchased from
Calbiochem (Darmstadt, Germany). STAT3 decoy and scrambled
ODNweresynthesized and purified aspreviously.[7,8] TheSTAT3
decoy ODN sequence was 59-CATTTCCCGTAAATC-39,3 9-
GTAAAGGGCATTTAG-59 and the scrambled ODN sequence
was 59-CATCTTGCCAATATC-39,3 9-GTAGAACGGTTA-
TAG-59. The sense and antisense strands were annealed and
purified by HPLC.
RNA isolation and real-time PCR assay
RT-PCR was performed as manufacturer’s instructions. Briefly,
total RNA was isolated using TRIzol (Invitrogen, Carlsbad, CA) as
previous described.[7] And cDNA were synthesis using the M-
MLV reverse transcriptase (Invitrogen, Carlsbad, CA).[7] Quan-
titative real-time PCR was performed by using SYBR Green kit
(Bio-rad) on Opticon Monitor (Bio-rad). The assays were initiated
with 15 min at 95uC, and then 40 cycle of 15 s at 94uC, 1 min at
58uC, 1 min at 72uC. The primers sequences were listed in
supplementary table S1. Relative mRNA expression levels of
interested gene were calculated using the 2
-DDCt method.
Mdr1 promoter luciferase reporter plasmid construction
The pGL3-mdr1 promoter luciferase reporter plasmid contains
a 617 bp fragment of mdr1 genomic sequence upstream of the
initiating ATG. It includes potential STAT3 binding sites as
verified by ChIP. This fragment was amplified using the following
primers: 59- CTAGGTACCTCAAAGGTGTTAGGAAGCA-
GAAAG-39 and 59-CAGGCTAGCTGAAAGCCTGACACTT-
GGGAAC-39, and subcloned into KpnI and NheI sites of pGL3-
Basic vector (Promega, Madison, WI). The reporter plasmids were
controlled by sequencing. For the mutation of potential STAT3
binding site, overlap-PCR was used and the mutated sequence was
shown in table 1.
Dual-luciferase reporter plasmid assay
6.25 ng pGL3-STAT3-TK-luciferase reporter vector or pGL3-
TK-luciferase control construct with 0.625 ng of pRL-TK were
co-transfected by lipofectamine 2000 (Invitrogen, Carlsbad, CA).
After 5 h, cells were cultured in fresh medium for 24 h. The
activities of luciferases are measured by Dual-Glo
TM Luciferase
Assay System (Promega, Madison, WI) according to the
manufacturer’s instruction by a luminometer (PerkinElmer
1420). To correct for variations in transfection efficiencies, the
firefly luciferase values were normalized against renilla luciferases.
For STAT3 decoy ODN inhibition assay, the plasmids and decoy/
scrambled ODN (200 nM) were co-transfected. Triplicates were
performed for each transfection study and three individual
experiments were conducted.
Drug accumulation
Accumulations of adriamycin in drug sensitive or resistant cells
were measured by using flow cytometry. 3610
5 cells in 1 ml were
plated in 6-well plate. After 24 h, cells were pretreated with
indicated concentrations of JSI-124 or transfected with 200 nM
decoy/scrambled ODN for 24 h, and then exposed with
adriamycin or rhodamine 123 for 90 min at 37uC. After three
washes with ice-cold PBS, the cells were resuspended and detected
with flow cytometer. The ratio of MFI over control was calculated
as follow: [MFI of adriamycin (Rh123) in treatment group]/[MFI
of adriamycin (Rh123) in control group].
Cell proliferation assay
Cell proliferation was examined by tritiated thymidine (
3H-
dThd) incorporation or CCK-8 kit. The K562/A02 and K562
cells (4610
4/well) were cultured in 24-well plate for 24 h, and JSI-
Table 1. Mutation sequence of potential STAT3 binding sites.
Potential binding site 1 (-330,-322) Potential binding site 2 (+64,+72)
Wide type AATTTCCCTTAACTA TCTTTCCACTAAAGT
STAT3M1 AATCGCCCTTGACTA
STAT3M2 TCTCGCCACTGAAGT
Consensus sequence 5’-TTMXXXDMA-3’, where D is A, G, or T and M is A or C.
In bold is the consensus SIE motif, and the bold underlined letters correspond to the mutated bases from the SIE motif.
doi:10.1371/journal.pone.0020965.t001
STAT3 Up-Regulates mdr1 in Drug-Resistant Leukemia
PLoS ONE | www.plosone.org 2 June 2011 | Volume 6 | Issue 6 | e20965124 was added into the wells at the indicated concentrations and
incubated for another 18 h or 42 h, and then pulsed for the
remaining 6 h with [
3H]thymidine (3.75 mCi/1 ml) (Amersha
Biosciences, UK). [
3H]Thymidine incorporation was analyzed by
liquid scintillation counting.
For CCK-8 assay, 1610
4 cells/well in 100-ml medium were
cultured in 96-well plate for 24 h. The K562/A02 and K562 cells
were treated with different concentrations of adriamycin (or
daunorubicin) combined with 1 mM JSI-124. Additionally, the
cells were also transfected with 200 nM STAT3 decoy/scrambled
ODN by lipofectamine 2000 for 6 h, and then refreshed with
medium containing indicated concentration of adriamycin. After
cultured for 48 h, 10 ml of Cell Counting Kit-8 reagent (Dojindo
Molecular Technologies, Gaithersburg, MD) was added to each
well and incubated for another 3 h at 37uC. The plates were read
at A450 nm-630 nm using a microplate reader (Bio-Rad). The
inhibition ratio was calculated by following formula: inhibition
(%) = (1-experimental OD/control OD) 6100%. An average of
at least three triplicates from three separate experiments was
calculated. The relative inhibition rates were represented with the
O.D. value of the control group set as zero.
Western blots
As described previously, [7] the extracts were resolved by SDS-
PAGE and transferred onto PVDF membranes (Millipore, Bed-
ford, MA). The bands were detected with the correspondence
antibodies.
Chromatin immunoprecipitation (ChIP) assays
K562/A02 cells were transfected with 200 nM STAT3 decoy/
scrambled ODN for 12 h. ChIP was done using a ChIP assay kit
(Upstate Biotechnology, Temecula, CA) according to the manu-
facturer’s instructions. Briefly, proteins were cross-linked with
DNA, and sheared using a sonicator. STAT3/DNA complexes
were precipitated either by anti-STAT3 antibody or by rabbit IgG
as the negative control. And then the anti-STAT3/STAT3/DNA
complex was collected by Protein G Agarose. The amount of
immunoprecipitated DNA was assessed by semiquantitative PCR
using primers spanning the different potential STAT3 binding
region in mdr1 promoter as shown in table 2. The conditions for
PCR reactions were as follows: 94uC for 5 min, 35 cycles at 94uC
for 30 s, 57uC for 40 s, 72uC for 40 s, and a final extension at
72uC for 5 min. Enrichment in each immunoprecipitation was
determined by quantifying the intensities of the PCR product in
immunoprecipitated DNA versus 10% input DNA.
Statistical analysis
All of the values are presented as the mean 6 SD for three or
more individual experiments. SPSS software (version 11.5, SPSS
Inc.) was used to test for significance. Statistical significance was
determined as *P,0.01 and
#P,0.05 compared with control. NS =
non-significant.
Results
STAT3 was over-activated in adriamycin-resistant K562/
A02 cells
The activity of STAT3 is usually higher in MDR malignancies,
and inhibition of STAT3 activity might reverse the chemo-
resistance.[15] In this study, we concluded that the comparison of
K562 and K562/A02 constitutes a valid model to study induced
resistance for classical chemotherapy.[17,18] It was observed that
mRNA level of STAT3 was higher in adriamycin-resistant K562/
A02 cells (Fig. 1A), total STAT3 protein expression was increased,
and the phosphorylation levels of STAT3 (Y705, S727) were also
much higher in K562/A02 cells (Fig. 1B, C). By using STAT3-
dependent luciferase reporter construct, we observed that higher
STAT3 activity was shown in K562/A02 (Fig. 1D), which was
consistent with the results of western blot. P-gp was also strongly
expressed in drug-resistant cells but not in drug-sensitive cells at
mRNA levels (Fig. 1A) and protein levels (Fig. 1B, C). Meanwhile,
STAT3 target gene, such as bcl-xl, was also up-regulated in K562/
A02 cells (data not shown). To further confirm the results,
adriamycin-resistant MCF-7/ADR and sensitive MCF-7 cancer
cell line were analyzed. Compared with MCF-7 cells, the
expression and phosphorylated levels of STAT3 were higher in
adriamycin-resistant MCF-7/ADR cells (Fig. S1A, B), which was
concomitant with strongly expressed P-gp (Fig. S1A, B). Overall,
these data show that the MDR phenotype is accompanied by
constitutively activated STAT3 signaling pathway.
STAT3 decoy ODN reversed adriamycin resistance
through downregulation of mdr1 in K562/A02 cells
STAT3 decoy ODN was used as an efficient method to inhibit
the activity of STAT3.[7,8] To assess whether STAT3 decoy
ODN blocks the transcription activity of STAT3 in K562/A02
cells, the STAT3 activity was analyzed by dual-luciferase reporter
assay after co-transfection of reporter plasmid and decoy/
scrambled ODN. As shown in Fig. 2A, STAT3 decoy ODN
reduced transcriptional activity of STAT3 compared with
scrambled ODN, while it could not block the activation of
STAT6, indicating the specificity of STAT3 decoy ODN (Fig. 2A).
However, the expression of STAT3 and the phosphorylation of
Y705-STAT3 showed no detectable changes after ODN treat-
ment, which were consistent with previous report (Fig. 2A).[19]
To elucidate the relationship between STAT3 and MDR, we
firstly investigated whether blocking the activation of STAT3
could reverse adriamycin resistance under our experimental
conditions. As shown in Fig. 2B, blockade of STAT3 activation
with STAT3 decoy ODN significantly increased the inhibition
rate of K562/A02 cells by adriamycin, indicated that the
cytotoxicity of adriamycin was promoted through inhibition of
STAT3. Meanwhile, the similar results were obtained in MCF-7/
ADR cells (Fig. S2A). Secondly, we analyzed the transcription and
expression levels of mdr1. As shown in Fig. 2C, STAT3 decoy
ODN but not scrambled ODN obviously decreased the transcrip-
Table 2. The primer sequences for ChIP.
Primer sequence
ChIP-1 sense 5’-CAGCAATGAATACCTTTGGCTG-3’
antisense 5’-CTAATAGAACCGAGCAAAAGATGC-3’
ChIP-2 sense 5’-GTTCAAGATCAGCCTAGTCAATGTG-3’
antisense 5’-TACCACTCCGCAATCCTACTTTTC-3’
ChIP-3 sense 5’-CTCTTTGGACTGAGTGGAAACTTG-3’
antisense 5’-TTGCCCTCCTTAGCATTCTTTG-3’
ChIP-4 sense 5’-GGTTAGCACCTTACCTGCTGTG-3’
antisense 5’-AATCTGCACCTTCTTGTCCTCC-3’
ChIP-5 sense 5’-CTTTTCAAAGGTGTTAGGAAGCAG-3’
antisense 5’-GAATTTCCAGGAGGAATGTTCTG-3’
ChIP-6 sense 5’-TCAACCTGTTTCGCAGTTTCTC-3’
antisense 5’-TAGTAGCTCCCAGCTTTGCGTG-3’
doi:10.1371/journal.pone.0020965.t002
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mdr1 transcripts were decreased to 62.7% by treating with 200 nM
STAT3 decoy ODN (p,0.05), whereas other MDR-associated
genes, such as MRP1 and BCRP1, showed no obvious changes
(data not shown). Simultaneously, the expression of P-gp was also
reduced to 42.7% when compared with control (Fig. 2C). Similar
phenomena were observed in MCF-7/ADR cells (Fig. S2B).
Finally, the intracellular adriamycin accumulation was explored
after STAT3 decoy ODN treatment by using flow cytometry
method. The results demonstrated that the accumulation of
adriamycin was enhanced in K562/A02 or MCF-7/ADR cells
treated with STAT3 decoy ODN, but did not in K562 or MCF-7
cells (Fig. 2D, Fig. S2C). Rhodamine-123, P-gp substrate, was also
used to evaluate intracellular accumulation, and the MFI of
rhodamine-123 in cells treated with STAT3 decoy ODN was
elevated (Fig. 2D), revealing that P-gp-medicated rhodamine-123
efflux can be inhibited by blocking of STAT3 activation. These
results suggested that deactivation of STAT3 could increase drug
accumulation by suppressing mdr1 transcription.
Inhibiting STAT3 led to down-regulation of mdr1 and
increased K562/A02 drug sensitivity
To further confirm our observation that deactivation of STAT3
could reverse the drug resistance, JSI-124, a selective inhibitor for
JAK/STAT3, was further used.[20] JSI-124 down-regulated the
phosphorylation of STAT3 in K562/A02 cells in a dose-
dependent manner but the total STAT3 level was not influenced
(Fig. 3A), and JSI-124 dose- and time-dependently inhibited
proliferation of K562/A02 cells when co-treated with 1 mg/ml
adriamycin (Fig. 3A). After treated for 24 h, the inhibition ratios
were 43%, 50% and 63% for 0.32 mM, 1.25 mM and 2.5 mM JSI-
124, respectively. And the inhibition ratios rose to 55%, 70% and
79% after treated for 48 h. When treated with different
concentrations of adriamycin combined with 1 mM JSI-124 for
48 h, JSI-124 induced about 8-fold reduction of IC50 in
adriamycin-resistant K562/A02 cells, but did not in K562 cells
(Fig. 3B). Similarly, the inhibitory effect of adriamycin on MCF-7/
ADR cell proliferation was augmented by JSI-124 (Fig. S3A).
At the same time, mdr1 transcripts were decreased by 62% and
75% when treated with 1.25 mMa n d2 . 5mM JSI-124 respectively
(p,0.01)(Fig.3C),andtheexpressionlevelofP-gpwasalsodecreased
by JSI-124 in a dose-dependent manner. P-gp was reduced by 53%
and 71% after treated with 1.25 mMa n d2 . 5mM JSI-124 for 36 h,
respectively (Fig. 3C). Compared with control, JSI-124 dose-
dependently improved the accumulation of adriamycin or rhoda-
mine-123 in K562/A02 cells, but not in K562 cells (Fig. 3D).
Consistent with these above, JSI-124 also dose-dependently attenu-
a t e dt h ee xp r e s si o no fmd r - 1a n dP- g pinM CF - 7 / A D Rc e l ls(p,0.05)
(Fig. S3B), and enhanced the accumulation of adriamycin in MCF-7/
ADR cells, but not in MCF-7 cells (Fig. S3C).
Figure 1. STAT3 activation in adriamycin-resistant K562/A02 cells. (A) RT-PCR analysis of STAT3 and mdr1 in K562/A02 cells and K562 cells.
(B) Western blot analysis of total STAT3, phosphorylation of STAT3 and P-gp. (C) The histogram presented the relative expression levels of each
protein after normalization to their corresponding internal control. (D) STAT3 activation was detected by using luciferase reporter construct assay.
Both cells were co-transfected with pGL3-STAT3-TK-Luciferase or pGL3-TK-Luciferase and pRL-TK-luciferase, and then luciferase activity was
measured.
doi:10.1371/journal.pone.0020965.g001
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daunorubicin, the effect of JSI-124 on daunorubicin treated
K562/A02 cells was also investigated. We found that JSI-124
significantly increased the sensitivity of K562/A02 cells to
daunorubicin, and induced about 62-fold reduction of IC50 in
K562/A02 cells (Fig S4). Thus, our data shows that drug
sensitivity could be increased by suppression of STAT3
activation in multi-drug resistance cells.
Mdr1 was transcriptional regulated by STAT3
The possibility that STAT3 participated in the regulation of
mdr1 transcription was explored. Computer-assisted searches of
potential STAT3 binding sites within mdr1 promoter region
revealed that there were seven possible sites containing putative
STAT3 DNA binding elements by using TFSEARCH and
TRANSFAC database (predicting transcription factor binding
sites), these regions are located at different position of mdr1
Figure 2. STAT3 decoy ODN increased the drug sensitivity via inhibiting the transcription of mdr1 and increasing the accumulation
of adriamycin. (A) Luciferase reporter assay and western blot were used to detect the STAT3 activation and expression after inhibiting by decoy
ODN. K562/A02 cells were co-transfected with STAT3 or STAT6-Luciferase reporter construct and decoy/scrambled ODN, and then luciferase activity
was measured. Total STAT3, pY705 STAT3 were detected by western blotting. (B) STAT3 decoy ODN increased the sensitivity of K562/A02 cells to
adriamycin. K562/A02 cells were transfected with 200nM STAT3 decoy or scrambled ODN. After 6h, different concentrations of adriamycin were
added and incubated for 48h followed by the CCK-8 assay. (C) STAT3 decoy ODN inhibited the transcription and expression of mdr1. K562/A02 cells
were transfected with STAT3 decoy or scrambled ODN, and mRNA and protein levels of mdr1 were measured by real time-PCR and western blotting.
(D) STAT3 decoy ODN increased the accumulation of adriamycin and rhodamine 123 into K562/A02 cells. K562/A02 and K562 cells were pretreated
with the STAT3 decoy or scrambled ODN, and then treated with adriamycin or rhodamine 123. Fluorescence intensity of adriamycin and rhodamine
123 were determined by flow cytometry.
doi:10.1371/journal.pone.0020965.g002
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sequence 59-TTMXXXDMA-39 was used for comparison.[21,22]
To further identify whether STAT3 could bind to mdr1
promoter in K562/A02 cells, ChIP assays were performed,
immunoprecipitated and inputted DNA were amplified using the
primers covering the suggested STAT3 binding sites as shown in
Fig. 4A. Firstly, the ChIP results exhibited that STAT3 could bind
to the consensus sequence located at -157,+159 of mdr1
promoter, and STAT3 decoy ODN depressed the binding
(Fig. 4B). However, no binding of STAT3 was found in other
regions of mdr1 promoter. Next, pGL3-mdr1-promoter luciferase
reporter vector which contains the two potential STAT3 binding
sites was constructed, and reporter assay was used to confirm
whether STAT3 participated in the transcription of mdr1.A s
shown in Fig. 4C, mdr1 promoter mediated luciferase expression
was effectively initiated, STAT3 decoy ODN but not scrambled
ODN decreased the luciferase activity. Meanwhile, co-transfection
with STAT3C plasmid, which expressed constitutively activated
Figure 3. JSI-124 increased the sensitivity of K562/A02 cells to adriamycin through down-regulation of mdr1. (A) JSI-124 inhibited
phosphorylation of STAT3 and the proliferation of K562/A02 cells. Cells were cultured in medium containing 1 mg/ml adriamycin and different
concentrations of JSI-124, and proliferation was detected with [
3H] thymidine incorporation. STAT3 and pY705STAT3 were measured by western
blotting. (B) The cells were cultured with different concentrations of adriamycin combined with 1 mM of JSI-124 followed by the CCK-8 assay. (C) JSI-
124 inhibited the transcription of mdr1 and expression of P-gp. After being treated with JSI-124 as indicated concentrations for 24 h, mRNA level of
mdr1 in K562/A02 cells was detected using real time-PCR. P-gp was examined by western blotting after being treated for 36h. (D) JSI-124 increased
the accumulation of adriamycin into K562/A02 cells. Cells were pretreated with JSI-124 for 24h, and then treated with adriamycin or rhodamine 123
for 90min. Fluorescence intensity were determined by flow cytometry.
doi:10.1371/journal.pone.0020965.g003
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PLoS ONE | www.plosone.org 6 June 2011 | Volume 6 | Issue 6 | e20965Figure 4. Mdr1 was transcriptional regulated by STAT3. (A) The sketch map of predicted STAT3 binding sites within mdr1 promoter. The ATTC,
transcriptional start site was as +1, and ATG is as translation start site. The putative STAT3 binding sites are shown and their locations are labeled. Six
sets of PCR primers, designated as ChIP-1, ChIP-2, ChIP-3, ChIP-4, ChIP-5 and ChIP-6, were used for amplification of the potential STAT3 binding sites
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mediated luciferase activity in K562/A02 cells, accompanied by
the enhanced expression of P-gp (Fig. 4C right). Finally, to more
definitively map the STAT3 binding site and its functionally
relevant in mdr1 promoter, the potential STAT3 binding region at
2330,2322 and +64,+72 were mutated separately, and their
luciferase activity were assayed. The results showed that mutation
at +64,+72 region, but not 2330,2322 region, lead obviously
reduction of the transcription activity (Fig. 4D). These findings
indicated that the DNA sequence at +64,+72 region was
recognized by STAT3 and responsible for mdr1 transcription. All
these results suggested that STAT3 could bind with mdr1 promoter
sequence and participated in the regulation of mdr1 transcription.
Discussion
The effectiveness of chemotherapy is seriously limited by MDR
which mediated mainly by P-gp. Since the early 1980s, some
compounds were found to overcome P-gp-mediated MDR.
However, they had only limited success in clinical trials.
Therefore, the characterization of signaling pathways sustaining
MDR is thus essential for designing rational novel therapies for
MDR leukemia. This notion is supported by the data in the
present study showing that inhibition of STAT3 pathway down-
regulated P-gp and partly reversed P-gp mediated MDR in
leukemia cells.
Our previous cumulative evidences supported that activated
STAT3 might be a target for anti-tumor strategy and STAT3
decoy ODN could be an ideal tool for inhibiting STAT3.[7,8,23]
In this study, it was demonstrated that STAT3 was more activated
in adriamycin resistant K562/A02 cells (Fig. 1), which was
consistent with drug-resistant ovarian cancer.[15] P-gp was also
frequently over-expressed in leukemia.[1] A hypothesis was that
STAT3 might be involved in MDR. As shown in Fig. 2 and Fig. 3,
blocking of STAT3 by decoy ODN or JSI-124 increased the
sensitivity of MDR cells to adriamycin and decreased the
transcription of mdr1 and expression of P-gp, so do Jak2 specific
inhibitor AG490 (Figure S5). Similar results were displayed in
another kind of adriamycin-resistant cell line MCF-7/ADR (Fig.
S1, S2, and S3).
By using STAT3 decoy ODN or JSI-124, we verified the
hypothesisthatdecreasetheactivationofSTAT3couldenhance the
inhibition effect of adriamycin on K562/A02 cells. The STAT3
scrambled ODN could also slightly inhibit proliferation of K562/
A02 cells in our experiment (Fig. 2B), in part because it mildly
inhibited the activity of STAT3 and transcription of mdr1 (Fig. 2A,
2C). In our further research, optimizations of the STAT3 decoy/
scrambled ODN and delivery system should be resulted in more
profound inhibition effects. JSI-124 could dose- and time-
dependent synergistically increase the adriamycin mediated prolif-
eration inhibition in K562/A02 cells but not parental K562 cells
(Fig. 3A, 3B), itwassimilar with theprevious reportindrug-resistant
ovarian cancer.[15] JSI-124 could also significantly increase
adriamycin-induced apoptosis (data not shown). Otherwise,
STAT3C could promote the transcription of mdr1 (Fig. 4C). ChIP
and mutation assay were used to further confirm the STAT3
binding site and its functionally relevant in mdr1 promoter. The
results show that +64,+72 region should be the binding site of
STAT3 (Fig. 4B, 4D). Like other members of ABC family such as
ABCG2 and ABCC10, mdr1 gene was transcribed by a TATA-less
promoter, and many transcription binding sites were identified at
the 59 untranslated region (UTR), such as AP-1 and AP-2. Our
research demonstrated the STAT3 binding site was also in the
59UTR of mdr1 gene. Further more, additional cell lines are needed
to make a generalization statement related to STAT3 and mdr1,i t
was also needed to evaluate whether other STAT genes, such as
STAT1 and STAT5, took part in the regulation of mdr1.
How was the transcription of mdr1 regulated? Our data
suggested that STAT3 could take part in regulating the
transcription of mdr1. Regulation of mdr1 gene transcription was
complicated, and yet was not clearly known. Numerous positive
and negative elements, as well as epigenetic control, were involved
in the process. Several transcription factors could bind with
elements of mdr1 promoter. For example, NF-kB played an
important role in regulation of mdr1 transcription in drug
resistance cancer cells.[24] The protein kinase systems, such as
MAPK kinase, were associated with the regulation of mdr1.[25]
Other signal path, such asDNp73a, FOXO3a and hedgehog, also
took part in mdr1 transcription in gastric carcinoma and leukemia,
respectively.[26,27,28] In a recent study, it was demonstrated that
Nanog/STAT3 complex took part in the transcription of mdr1 in
breast and ovarian tumor cells.[16] Inhibition of STAT3
decreased mdr1 mRNA in ovarian cancer cells.[29] In our present
study, the ChIP and luciferase results demonstrated that STAT3
could bind to the promoter of mdr1 and initiated its transcription,
however, whether the binding was STAT3 alone or with other
proteins needed to be further identified. In the recent article, Lee
et al. reported that persistently activated STAT3 play important
role in maintenance of NF-kB activity, [30] it was conjectured that
STAT3 might play roles coupled with NF-kB. Whether STAT3
target genes were also associated with mdr1 in our experiments was
needed to be further identified. Recently, Bewry et al reported that
drug resistance correlated with increased pTyrSTAT3, and
resistance was associated with increased levels of the STAT3
target genes Bcl-xl, Mcl-1, and survivin.[31] In our results, we
elucidated the molecular mechanism of transcription regulation of
mdr1 by STAT3.
In summary, it was demonstrated that the activation of STAT3
was higher in drug resistant K562/A02 leukemia cells, and also in
MCF-7/ADR cells. And STAT3 activation inhibitors sensitized
K562/A02 cells to adriamycin. STAT3 was involved in the
regulation of mdr1 transcription by binding with its promoter.
Therefore, the present study provided a molecular mechanism of
transcriptional regulation of mdr1 by STAT3, and suggested that
STAT3 could be potential target in treating drug resistant
leukemia. In addition, our data may also be relevant for the early
detection of resistance who suffering leukemia.
Supporting Information
Figure S1 STAT3 activation in adriamycin-resistant
MCF-7/ADR cells. (A) RT-PCR analysis of STAT3 and mdr1
by ChIP assay, respectively. (B) ChIP assay was performed using anti-STAT3 antibody or irrelevant IgG antibody as negative control. Input: total
genomic DNA used as control for the PCR. The histogram represented the intensities of the PCR product in immunoprecipitated DNA versus 10%
input DNA of ChIP-6 primer. (C) Luciferase reporter assay was used to detect the STAT3-dependent transcriptional activation. pGL3-mdr1 promoter
luciferase construct alone or with STAT3 decoy/scrambled ODN or with pcDNA3.0, STAT3C plasmid were co-transfected and luciferase activity was
detected. STAT3C increased the total and activated STAT3, and promoted the expression of P-gp. K562/A02 cells were transfected with STAT3C for 40
h. Proteins were extracted and examined by western blotting. (D) Identification of STAT3 binding site in mdr1 promoter. Constitution of pGL3-mdr1-
luciferase reporter and the mutated plasmid were described as in Materials and Methods, and their luciferase activity was assayed.
doi:10.1371/journal.pone.0020965.g004
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of total STAT3, phosphorylated STAT3 and P-gp levels.
(TIF)
Figure S2 STAT3 decoy ODN increased the drug
sensitivity via inhibiting the transcription of mdr1 and
increasing the accumulation of adriamycin. (A) STAT3
decoy ODN increased the sensitivity of MCF-7/ADR cells to
adriamycin. MCF-7/ADR cells were transfected with 100nM
STAT3 decoy or scrambled ODN. After 6h, different concentra-
tions of adriamycin were added and incubated for 48h followed by
the CCK-8 assay. (B) STAT3 decoy ODN inhibited the
transcription and expression of mdr1. MCF-7/ADR cells were
transfected with STAT3 decoy or scrambled ODN, and mRNA
and protein levels of mdr1 were measured by real time-PCR and
western blotting. (C) STAT3 decoy ODN increased the accumu-
lation of adriamycin into MCF-7/ADR cells. MCF-7/ADR and
MCF-7 cells were pretreated with the STAT3 decoy or scrambled
ODN, and then treated with adriamycin. Fluorescence intensity of
adriamycin was determined by flow cytometry.
(TIF)
Figure S3 JSI-124 increased the sensitivity of MCF-7/
ADR cells to adriamycin through down-regulation of
mdr1. (A) The cells were cultured with different concentrations
of adriamycin combined with 0.3 mM of JSI-124 followed by the
CCK-8 assay. (B) JSI-124 inhibited the transcription of mdr1 and
expression of P-gp. After being treated with JSI-124 as indicated
concentrations for 24 h, mRNA level of mdr1 in MCF-7/ADR
cells was detected using real time-PCR. P-gp was examined by
western blotting after being treated for 36h. (C) JSI-124 increased
the accumulation of adriamycin into MCF-7/ADR cells. Cells
were pretreated with JSI-124 for 24h, and then treated with
adriamycin for 90min. Fluorescence intensity were determined by
flow cytometry.
(TIF)
Figure S4 JSI-124 increased the sensitivity of K562/A02
cells to daunorubicin. K562/A02 cells were treated with
different concentrations of daunorubicin combined with 1 mMo f
JSI-124 for 48h followed by the CCK-8 assay.
(TIF)
Figure S5 Jak2 specific inhibitor AG490 enhanced the
drug sensitivity of K562/A02 cells via down-regulating P-
gp. (A) The K562/A02 cells were treated with different
concentrations of adriamycin in the presence of 100 mM/50 mM
of AG490 for 48h followed by the CCK-8 assay. An average of at
least three triplicates from three separate experiments was
calculated. The inhibition ratio was calculated by following
formula: inhibition (%) = (1-experimental OD/control OD)
6100%. (B) mRNA level of MDR1 was detected using real time-
PCR method. Relative expressions were calculated. (C) After
being treated with AG490 at indicated concentrations for 36h, the
whole-cell extracts were obtained. P-gp, pSTAT3 (Y705) and
STAT3 were then examined by western blotting.
(TIF)
Table S1 The primer sequences for real time-PCR.
(DOC)
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